Who are Eliglustat GZ385660's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cerdelga, Zavesca, Miglustat (Zavesca).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eliglustat-gz385660.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Eliglustat GZ385660 — Competitive Intelligence Brief

Eliglustat GZ385660 (Eliglustat GZ385660) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Glucosylceramide synthase inhibitor. Area: Rare/Genetic Disorders.

phase 3 Glucosylceramide synthase inhibitor Glucosylceramide synthase (GCS) Rare/Genetic Disorders Small molecule Live · refreshed every 30 min

Target snapshot

Eliglustat GZ385660 (Eliglustat GZ385660) — Sanofi. Eliglustat is a glucosylceramide synthase (GCS) inhibitor that reduces the production of glucosylceramide, a lipid that accumulates in Gaucher disease.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Eliglustat GZ385660 TARGET	Eliglustat GZ385660	Sanofi	phase 3	Glucosylceramide synthase inhibitor	Glucosylceramide synthase (GCS)
Cerdelga	ELIGLUSTAT	Sanofi	marketed	Glucosylceramide Synthase Inhibitor [EPC]	Ceramide glucosyltransferase	2014-01-01
Zavesca	MIGLUSTAT	AstraZeneca	marketed	Glucosylceramide Synthase Inhibitor [EPC]	Lysosomal alpha-glucosidase	2003-01-01
Miglustat (Zavesca)	Miglustat (Zavesca)	University of Washington	marketed	Glucosylceramide synthase inhibitor	Glucosylceramide synthase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-03-07 — Zavesca · 12419937 · Method of Use · US
2033-03-07 — Zavesca · 11278599 · Method of Use · US
2033-03-07 — Zavesca · 10512677 · Method of Use · US
2035-09-30 — Zavesca · 10961522 · Method of Use · US
2035-09-30 — Zavesca · 10208299 · Compound · US
2035-09-30 — Zavesca · 11753632 · Method of Use · US
2036-12-29 — Zavesca · 11278601 · Formulation · US
2036-12-29 — Zavesca · 12414985 · Method of Use · US
2037-08-12 — Zavesca · 10857212 · Method of Use · US
2038-09-16 — Zavesca · 12246062 · Method of Use · US

Sponsor landscape (Glucosylceramide synthase inhibitor class)

Sanofi · 1 drug in this class
University of Washington · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Eliglustat GZ385660 — Competitive Intelligence Brief. https://druglandscape.com/ci/eliglustat-gz385660. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab